Oxy Watchdog

Keeping An Eye On OxyContin

  • Contact Watchdog

    Send comments, tips, and general thoughts to oxywatchdog@gmail.com.
  • Subscribe

  • Twitter Updates

  • Advertisements

New opioid painkiller may rival OxyContin in the marketplace

Posted by Oxy Watchdog on September 30, 2010

As the pharmaceutical companies Grunenthal and Johnson & Johnson release positive final-stage trial results for their new opioid painkiller tapentadol extended-release, market predictors estimate the new drug will rival or possibly even replace OxyContin as the top medication for chronic pain. According to this article in Trading Markets.com, Datamonitor forecasts sales to reach over $800 million by 2019. If approved for sale in the U.S., tapentadol will be the first new opioid to reach the marketplace in over 25 years. As an opioid-based, Schedule II drug like OxyContin, tapentadol may also become highly addictive and should be used under careful supervision, states Johnson & Johnson in this press release.


One Response to “New opioid painkiller may rival OxyContin in the marketplace”

  1. […] This post was mentioned on Twitter by Shane Applegate, Oxy Watchdog. Oxy Watchdog said: New opioid painkiller may provide addicts with an alternative to OxyContin (and give Purdue a run for their money) : http://t.co/rsh0NSb […]

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: